Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
R092670 · 1 trial · 1 indication
| Name | Type | Description |
|---|---|---|
| R092670 | DRUG | - |
Inclusion Criteria: * Patients diagnosed with schizophrenia * for at least 1 year before screening * meet PANSS score criteria * must agree to hospitalization for a minimum of 14 days * body mass index (BMI) \<35.0 kilogram (kg)/meter (m)2. Exclusion Criteria: * Patients who are involuntarily com...
R092670 is an investigational small molecule being developed for the treatment of schizophrenia. It is a psychiatry therapeutic that has been studied in a Phase 2 clinical trial. The drug is not approved and remains in clinical development.
R092670 is being developed by Johnson & Johnson, a company traded on the New York Stock Exchange under the ticker JNJ. The drug is an investigational small molecule intended for the treatment of schizophrenia.
R092670 is in Phase 2 of clinical development. It has completed one Phase 2 trial, which was a randomized, double-blind, uncontrolled study involving 250 participants with schizophrenia. The drug is investigational and not yet approved.
R092670 has been studied in one completed clinical trial, identified as NCT00074477. This Phase 2 study, titled 'Safety and Efficacy of an Anti-Psychotic in Patients With Schizophrenia,' enrolled 250 participants aged 18 years and older.
R092670 is not FDA approved. It is an investigational drug that has completed a Phase 2 clinical trial for schizophrenia. The drug is still in clinical development and has not received regulatory approval.